Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State
Executive Summary
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
You may also be interested in...
Tech Transfer Roundup: MD Anderson Inks Set Of IO Deals Covering US, UK, Japan, China
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
A Phoenix Turn For Tonix: Rising From Phase III Ashes With New PTSD Approach
In an exclusive interview, Seth Lederman, CEO of New York-based Tonix Pharmaceuticals, talks about the company’s R&D rollercoaster ride and how it plans to keep its lead asset on track for approval as a treatment for post-traumatic stress disorder.
Tech Transfer Roundup: Academia's Role In De-Risking Novel Science
The Sanford Burnham Prebys institute is driving innovation in areas like neurodegenerative disease and immuno-oncology. Plus the latest tech transfer deals: two in cancer, one in asthma/allergies and another in lipid nanoparticle technology.